Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.

Requena, S. ; Lozano, AB. ; Caballero, E. ; García, F. ; Nieto, MC. ; Téllez, R. ; Fernández, JM. ; Trigo, M. ; Rodríguez-Avial, I. ; Martín-Carbonero, L. ; Miralles, P. ; Soriano, V. ; de, Mendoza, C. ; HIV-2 Spanish Study Group ; Rodríguez, C. ; Vera, M. ; Del, Romero, J. ; Marcaida, G. ; Ocete, MD. ; Caballero, E. ; Aguilera, A. (Universidad de Zaragoza) ; BENITO, R. ; de, Lejarazu, RO. ; Rojo, S. ; Eirós, JM. ; Ramos, C. ; García, J. ; Paz, I. ; Trigo, M. ; Diz, J. ; García-Campello, M. ; Rodríguez-Iglesias, M. ; Hernández-Betancor, A. ; Martín, AM. ; Ramos, JM. ; Gimeno, A. ; Sánchez, V. ; Gómez-Hernando, C. ; Cilla, G. ; Pérez-Trallero, E. ; Fernández-Pereira, L. ; Niubó, J. ; Hernández, M. ; López-Lirola, AM. ; Gómez-Sirvent, JL. ; Force, L. ; Cabrera, J. ; Pérez, S. ; Morano, L. ; Raya, C. ; González-Praetorius, A. ; Cifuentes, C. ; Peñaranda, M. ; Nieto, MC. ; Montejo, JM. ; Roc, L. ; Viciana, I. ; Lozano, AB. ; Fernández-Fuertes, E. ; Fernández, JM. ; García-Bermejo, I. ; Gaspar, G. ; Téllez, R. ; Górgolas, M. ; Miralles, P. ; Pérez, L. ; Valeiro, M. ; Aldamiz, T. ; Margall, N. ; Suárez, A. ; Rodríguez-Avial, I. ; Requena, S. ; Benítez-Gutiérrez, L. ; Cuervas-Mons, V. ; de, Mendoza, C. ; Barreiro, P. ; Soriano, V.

Resumen: Background: HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2.
Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with inte- grase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modal- ities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed.
Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1).
Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individ- uals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.

Idioma: Inglés

DOI: 10.1093/jac/dkz007

Año: 2019

Publicado en: The Journal of antimicrobial chemotherapy 74, 5 (2019), 1357-1372
ISSN: 1460-2091

Factor impacto JCR: 5.439 (2019)

Categ. JCR: INFECTIOUS DISEASES rank: 10 / 93 = 0.108 (2019) - Q1 - T1
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 22 / 270 = 0.081 (2019) - Q1 - T1
Categ. JCR: MICROBIOLOGY rank: 24 / 134 = 0.179 (2019) - Q1 - T1

Factor impacto SCIMAGO: 2.23 - Infectious Diseases (Q1) - Pharmacology (medical) (Q1) - Pharmacology (Q1) - Microbiology (medical) (Q1)

Financiación: info:eu-repo/grantAgreement/EC/FP7/223131/EU/Collaborative HIV and Anti-HIV Drug Resistance Network/CHAIN

Tipo y forma: Artículo (PostPrint)

Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)